株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

胃癌:治療薬パイプライン分析および2016年までの市場予測

Stomach Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

発行 GlobalData 商品コード 121312
出版日 ページ情報 英文 44 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
胃癌:治療薬パイプライン分析および2016年までの市場予測 Stomach Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
出版日: 2010年05月10日 ページ情報: 英文 44 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、胃癌市場について治療薬パイプライン分析および2016年までの市場予測を行っており、市場の特徴をはじめ、競合、パイプラインなどを評価分析し、将来の市場競争、企業プロファイルを盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 胃癌市場:市場の特徴

  • 概要
  • 市場規模
  • 市場予測および年複利成長率(CAGR)
  • 市場促進および阻害要因
  • 機会およびアンメットニーズ
  • 要点

第3章 競合のアセスメント

  • 概要
  • 戦略的競合企業の評価
  • 主な市販製品のプロファイル
  • 要点

第4章 パイプラインのアセスメント

  • 概要
  • 戦略的パイプラインの評価
  • 治療:臨床開発中の有望な治療薬
  • 臨床開発中の有望な治療薬の分子プロファイル
  • 胃癌市場:作用機序別臨床パイプライン
  • 胃癌:臨床開発段階別パイプライン
  • 中止/中断
  • 要点

第5章 将来の市場競争についての示唆

第6章 将来の企業

  • イントロダクション
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Merck & Co

第7章 付録

図表

目次
Product Code: GDHCPRT084

Abstract

Stomach Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData’s pharmaceutical and healthcare report, “Stomach Cancer - Drug Pipeline Analysis and Market Forecasts to 2016”, is an essential source of information and analysis on the global stomach cancer market. The report identifies the key trends shaping and driving the global stomach cancer market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products in the global stomach cancer segment.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global gastric cancer market is expected to value $1,313m in 2016. Most of the chemotherapies are already off-patent while Taxotere and Xeloda are expected to lose their patents during 2010 to 2011. Taxotere’s generic version, produced by Hospira, has already been approved in Europe through the decentralized procedure. The market is expected to be driven by the increase in demand due to the launch of promising targeted therapies currently in the late stage of development. The pending approval of Herceptin in the US and Japan will also boost the revenues generated in the gastric cancer market. However, the new therapies are not expected go off-patent before 2016. Therefore, the market is expected to witness strong growth in market revenues in the forecast period.

Scope

The scope of the report includes:
- Annualized global (gastrointestinal) stomach cancer market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data split across different phases by mechanism of action and emerging trends. The key classes of mechanism of action are mTOR inhibitors, PARP inhibitors, microtubule inhibitors, VEGFR inhibitors, multiple tyrosine kinase inhibitors, Heat Shock Protein 90 inhibitors, Eg5 inhibitors, Farnesyl-OH-transferase inhibitors, angiogenesis inhibitors and combinations of several existing chemotherapies.
- Analysis of the current and future competition in the global stomach cancer market. The key market players covered include GlaxoSmithKline, Novartis Pharmaceuticals, Merck & Co, Eli Lilly and Company, Amgen, Fresenius Biotech GmBH, ACT Biotech, Genta Incorporated and Bristol Myers-Squibb.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future stomach cancer market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global gastrointestinal (stomach) cancer market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global gastrointestinal (stomach) cancer market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global gastrointestinal (stomach) cancer market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 Stomach Cancer: Market Characterization 5
2.1 Overview 5
2.2 Stomach Cancer Market Size 5
2.3 Stomach Cancer Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Stomach Cancer Market 7
2.4.1 Drivers for the Stomach Cancer Market 7
2.4.2 Barriers for the Stomach Cancer Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Stomach Cancer Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profiles of Major Marketed Drugs in the Stomach Cancer Market 11
3.3.1 Herceptin (trastuzumab) 11
3.3.2 Taxotere (docetaxel) 12
3.3.3 Xeloda 14
3.3.4 Gleevec (imatinib) 15
3.4 Key Takeaway 16
4 Stomach Cancer Market: Pipeline Assessment 17
4.1 Overview 17
4.2 Strategic Pipeline Assessment 17
4.2.1 Technology Trends Analytic Framework 17
4.3 Stomach Cancer - Promising Drugs Under Clinical Development 19
4.4 Molecule Profile for Promising Drugs Under Clinical Development 19
4.4.1 Tykerb (Lapatinib) 19
4.4.2 Afinitor (Everolimus) 20
4.4.3 IMC-1121B (ramucirumab) 21
4.4.4 Cetuximab plus capecitabine and cisplatin 21
4.5 Stomach Cancer Market - Clinical Pipeline by Mechanism of Action 22
4.6 Stomach Cancer Market - Pipeline by Clinical Phase of Development 23
4.6.1 Stomach Cancer Market - Phase III Clinical Pipeline 23
4.6.2 Stomach Cancer Market - Phase II Clinical Pipeline 25
4.6.3 Stomach Cancer Market - Phase I Clinical Pipeline 29
4.7 Discontinued/Suspended Drugs for Stomach Cancer 30
4.8 Key Takeaway 30
5 Stomach Cancer: Implications for Future Market Competition 31
6 Stomach Cancer Market: Future Players in the Stomach Cancer Market 33
6.1 Introduction 33
6.2 GlaxoSmithKline 33
6.2.1 Company Overview 33
6.2.2 Business Description 33
6.3 Novartis Pharmaceuticals 35
6.3.1 Company Overview 35
6.3.2 Business Description 35
6.4 Eli Lilly and Company 36
6.4.1 Company Overview 36
6.4.2 Business Description 36
6.5 Merck & Co 37
6.5.1 Company Overview 37
6.5.2 Business Description 37
7 Stomach Cancer Market: Appendix 40
7.1 Definitions 40
7.2 Acronyms 40
7.3 Research Methodology 41
7.3.1 Coverage 41
7.3.2 Secondary Research 42
7.3.3 Forecasting 42
7.3.4 Primary Research 43
7.3.5 Expert Panels 44
7.4 Contact Us 44
7.5 Disclaimer 44
7.6 Sources 44

1.1 List of Tables
Table 1: Stomach Cancer Market Historical Revenues ($m), 2001-2009 6
Table 2: Stomach Cancer Market Forecasts ($m), 2009-2016 7
Table 3: Major Marketed Products Comparison in Stomach Cancer Market, 2010 16
Table 4: Stomach Cancer - Most Promising Drugs under Clinical Development, 2010 19
Table 5: Stomach Cancer - Phase III Clinical Pipeline, 2010 23
Table 6: Stomach Cancer - Phase II Clinical Pipeline, 2010 25
Table 7: Stomach Cancer - Phase I Clinical Pipeline, 2010 29
Table 8: List of Discontinued/Suspended Drugs for Stomach Cancer, 2010 30
Table 9: GlaxoSmithKline - Clinical Pipeline for Stomach Cancer, 2010 34
Table 10: Novartis Pharmaceuticals - Clinical Pipeline for Stomach Cancer, 2010 36
Table 11: Eli Lilly and Company - Clinical Pipeline for Stomach Cancer, 2010 37
Table 12: Merck & Co - Clinical Pipeline for Stomach Cancer, 2010 39

1.2 List of Figures
Figure 1: Stomach Cancer Market Historical Revenues ($m), 2001-2009 6
Figure 2: Stomach Cancer Market Forecasts ($m), 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Stomach Cancer Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Stomach Cancer Market, 2010 11
Figure 5: Technology Trends Analytic Framework - Stomach Cancer Market, 2010 18
Figure 6: Technology Trends Analytic Framework of the Stomach Cancer Pipeline - Description, 2010 18
Figure 7: Stomach Cancer Market - Clinical Pipeline by Mechanism of Action, 2010 22
Figure 8: Stomach Cancer Pipeline by Phase of Clinical Development, 2010 23
Figure 9: Implications for Future Market Competition in Stomach Cancer, 2010 31
Figure 10: Stomach Cancer Market - Clinical Pipeline by Company, 2010 33
Figure 11: GlobalData Methodology, 2010 41

Back to Top